ArticleEuropean journal of nuclear medicine and molecular imaging2017
Phase I/II trials of
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate Radiopharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Radiobiological evaluation of the therapeutic effect of silver-111 for the ISOLPHARM project.Frontiers in nuclear medicine · 2026Article
- Bifunctional chelators for radiorhenium: past, present and future outlook.RSC medicinal chemistry · 2022Review
- Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.Journal of clinical medicine · 2020Review
- Theranostic radiopharmaceuticals: established agents in current use.The British journal of radiology · 2018Review
- Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.The British journal of radiology · 2018Article
- Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.European journal of nuclear medicine and molecular imaging · 2018Article
- Single high dose versus repeated bone-targeted radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2017Article
- Imaging and dosimetry for radium-223: the potential for personalized treatment.The British journal of radiology · 2017Review
- A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.Physics in medicine and biology · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
purposeTo investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant prostate cancer, and to assess whether higher administered levels of activity are associated with a survival benefit.
methodsClinical data from 57 patients who received 2.5-5.1 GBq of
resultsA statistically significantly longer OS was associated with administered activities above 3.5 GBq in the 57 patients (20.1 vs 7.1 months, hazard ratio: 0.39, 95 % CI: 0.10-0.58, P = 0.002). A total of 379 bone lesions were identified in 22 patients. The mean of the patient mean absorbed dose was 19 (±6) Gy and the mean of the whole-body absorbed dose was 0.33 (±0.11) Gy for the 22 patients. The patient mean absorbed dose (r = 0.65, P = 0.001) and the whole-body absorbed dose (r = 0.63, P = 0.002) showed a positive correlation with disease volume. Significant differences in OS were observed for the univariate group analyses according to disease volume as measured from SPECT imaging of
conclusionThis study demonstrated that higher administered activities led to prolonged survival and that for a fixed administered activity, the whole-body and patient mean absorbed doses correlated with the extent of disease, which, in turn, correlated with survival. This study shows the importance of patient stratification to establish absorbed dose-response correlations and indicates the potential to individualise treatment of bone metastases with radiopharmaceuticals according to patient-specific imaging and dosimetry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.